Safety, pharmacokinetics, and pharmacodynamics of epratuzumab in Japanese patients with moderate-to-severe systemic lupus erythematosus: Results from a phase 1/2 randomized study.

导出 LinkOut

翻译打印收藏纠错

第一作者： Tomomi,Tsuru

第一单位： a PS Clinic , Fukuoka , Japan .

作者： Tomomi,Tsuru ^[1] ; Yoshiya,Tanaka ^[2] ; Mitsumasa,Kishimoto ^[3] ; Kazuyoshi,Saito ^[2] ; Seiji,Yoshizawa ^[4] ; Yoshinari,Takasaki ^[5] ; Tomoya,Miyamura ^[6] ; Hiroaki,Niiro ^[7] ; Shinji,Morimoto ^[8] ; Junichi,Yamamoto ^[9] ; Rocio,Lledo-Garcia ^[10] ; Jing,Shao ^[11] ; Shuichiro,Tatematsu ^[9] ; Osamu,Togo ^[9] ; Takao,Koike ^[12]

作者单位： a PS Clinic , Fukuoka , Japan . ^[1] b The First Department of Internal Medicine , School of Medicine, University of Occupational and Environmental Health , Kitakyushu , Japan . ^[2] c Immuno-Rheumatology Center, St Luke's International Hospital , Tokyo , Japan . ^[3] d Department of Rheumatology , Hamanomachi Hospital , Fukuoka , Japan . ^[4] e Department of Internal Medicine and Rheumatology , School of Medicine, Juntendo University , Tokyo , Japan . ^[5] f Department of Internal Medicine and Rheumatology , Clinical Research Institute, National Hospital Organization Kyushu Medical Center , Fukuoka , Japan . ^[6] g Clinical Education Center, Kyushu University Hospital , Fukuoka , Japan . ^[7] h Department of Internal Medicine and Rheumatology , Juntendo University Urayasu Hospital , Chiba , Japan . ^[8] i UCB Pharma , Tokyo , Japan . ^[9] j UCB Pharma , Slough , UK . ^[10] k UCB Pharma , Shanghai , P.R. China , and. ^[11] l NTT Sapporo Medical Center , Hokkaido , Japan. ^[12]

关键词 Epratuzumab Pharmacodynamics Pharmacokinetics Safety Systemic lupus erythematosus